Date:2/13/2013

(VEGF). This is likely to enable real-time analysis of tumors in the human body without the need for a blood draw or magnetic resonance imaging (MRI) test.  Every twenty four hours, the body of each human on our planet produces one million cancer cells. Our immune system fights these cancer cells and most often wins the battle every day. Due to weakness of the immune system and reasons that are still unknown, one cancer cell from these one million cells can remain in the body. This rogue cancer cell will then start to grow and can metastasize. The science and medical community unequivocally agrees that - were we capable of detecting these metastatic cancer cells before they grow to about 1 gram in critical mass (about 1 cc in volume) - current treatment modalities could defend against the cancer and save every life. PKC VEGF NIB will give cancer patients to hopefully never experience the pain and suffering of experiencing chemotherapy, tumor resection and death.  The first PKC commercial version of NIB for VEGF will be ready in about six months.

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Pharmaco-Kinesis Corporation (PKC)

PKC is an advanced m
'/>"/>

SOURCE Frost & Sullivan Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
3. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
4. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
5. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
6. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
7. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
8. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
9. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
10. Electronic Medical Records Progress from an Enterprise-Centric Solution to a Customer-Specific Application, Finds Frost & Sullivan
11. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market